Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05389722 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05389722: Completed Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

NCT05389722 is a Phase 1 study of Healthy Volunteers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05389722, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

Conditions Studied

Interventions

  • DRUG Rifampin
  • DRUG Itraconazole
  • DRUG Rosuvastatin
  • DRUG CC-92480
  • DRUG Digoxin

Study Locations (1)

Texas

  • Covance Clinical Research Unit - Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-06-09
Est. Completion 2022-11-12
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT05389722 record still lists

NCT05389722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 5 interventions - of which Rifampin is the first listed.

NCT05389722 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05389722 about?

NCT05389722 is a clinical study titled "A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants". The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

What is the current status of trial NCT05389722?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-06-09. Estimated completion is 2022-11-12.

What conditions does trial NCT05389722 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT05389722?

The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Rosuvastatin (DRUG), CC-92480 (DRUG), Digoxin (DRUG).

Who is sponsoring clinical trial NCT05389722?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05389722 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05389722's enrollment target sits among peer trials

24 204th of 283 higher than 66 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05389722, the US trial registry maintained by the National Library of Medicine. NCT05389722 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.